Clinical Trial Update: A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation [Phase 1]

View source ↗

Summary

Phase 1 study to evaluate safety, pharmacokinetics, and activity of GDC-6036 alone or in combination in participants with KRAS G12C-mutant advanced or metastati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• GDC-6036

Snippet

Sponsor: Genentech, Inc. | Conditions: Non-Small Cell Lung Cancer, Colorectal Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING